MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Pharma delivers another strong quarter for Johnson & Johnson

Pharma delivers another strong quarter for Johnson & Johnson

By

Pharma delivers another strong quarter for Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) shares rose today after the healthcare conglomerate reported Wall-Street-beating 3rd-quarter results, buoyed by its pharmaceuticals division.

New Brunswick, N.J.-based J&J posted profits of $3.0 billion, or $1.04 per share, on sales of $17.58 billion for the 3 months ended Sept. 30, for bottom-line growth of 13.4% on sales growth of 3.1% compared with Q3 2012.

Adjusted to exclude 1-time items, earnings per share reached $1.36, beating expectations on The Street by 4¢. That, and a boost for JNJ’s full-year earnings outlook, boosted share prices today to $90.37 apiece as of about 11:30 a.m., up 0.6%.

"Our 3rd-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers," chairman & CEO Alex Gorsky said in prepared remarks. "Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers."

Johnson & Johnson raised its adjusted earnings forecast for 2013 to $5.44-$5.49 per share, up from $5.40-$5.47. Analysts on The Street are looking for full-year adjusted EPS of $5.46.

Sales for the company’s medical device and diagnostics segment slipped 2% during the quarter to $6.93 billion, with U.S. sales down 4.2% to $3.15 billion and international sales down 0.1% to $3.78 billion. Leerink Swann analyst Danielle Antalffy said the below-consensus results for the device segment belies an uptick for J&J’s specialty surgical division. Sales for that business rose 4.9% to $626.0 million during the quarter.

"Overall, JNJ continues to ride the back of strong Pharma performance as recent product launches continue to exceed expectations," Antalffy wrote this morning in a note to investors. "And while below-consensus MD&D sales could perpetuate concerns that broader MedTech utilization trends remain weak, strong Surgical sales could actually signal potentially positive volume trends overall. While JNJ suffers several ‘weak’ spots – primarily in MD&D – the company should continue to benefit from positive tailwinds within Pharma and the ongoing Consumer turnaround, pushing shares higher still."

In case you missed it

RSS From Medical Design & Outsourcing

  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]